Nearly 500 people have already registered for OCRA’s International Gynecologic Cancer Conference®—the largest conference dedicated to the gynecologic cancer community—taking place on September 16–17. The conference is free, online, and open to all, and will include programming for ovarian, endometrial, cervical, and rare gynecologic cancers. For the first time, each of these diseases will have a dedicated Ask the Experts session. Learn … Continued
On June 1–2, the Ovarian Cancer Observatory—part of OCRA’s broader investment in research initiatives—convened its first in-person Forum in Vancouver. Roughly 50 of the field’s brightest clinicians, pathologists, and epidemiologists gathered for what became, in essence, a two-day think tank on preventing ovarian cancer. The Observatory is funded through a grant from OCRA and was … Continued
When Ovarian Cancer Research Alliance (OCRA) announced the launch of the Community Accelerated Research Exchange on World Ovarian Cancer Day, the response was immediate. More than 280 media mentions. Over 171 million people reached. Television and radio coverage in English and Spanish, in markets from San Francisco to Albany. The excitement is building—and it’s just … Continued
AI-Powered Platform Launch Sparks Nationwide Conversation The response to OCRA’s launch of the Community Accelerated Research Exchange was immediate and far-reaching. News outlets across the country picked up the story, generating more than 280 media mentions and reaching over 171 million people—a sign of just how much this groundbreaking platform, designed to connect patients, researchers, … Continued
OCRA is proud to announce the launch of the Rare Ovarian Cancer Collaborative Analytics (ROCCA) Platform, an international federated data network funded by OCRA to connect researchers globally and accelerate breakthroughs in rare ovarian cancer research. A collaborative approach to research for rare ovarian cancer ROCCA is launching with two foundational projects: one in mucinous … Continued
We Believe There’s a Better Way to Do Research So we created it. OCRA has launched the most ambitious initiative in our history. We believe it represents a fundamentally new way for research to work—one with the potential to accelerate discovery in gynecologic cancers while serving as a model for breakthroughs across all diseases. We … Continued
Platform, powered by AWS, connects patients, researchers, and clinicians to accelerate breakthroughs in gynecologic cancers [NEW YORK, NY – May 8, 2026] — Ovarian Cancer Research Alliance (OCRA) today announced the launch of the Community Accelerated Research Exchange, a first-of-its-kind, global, AI-powered ecosystem designed to transform how gynecologic cancer research is conducted—accelerating breakthroughs by connecting … Continued
On World Ovarian Cancer Day, May 8, the Global Ovarian Cancer Research Consortium announces a second $1 million USD grant along with AWS compute support to power research that aims to improve ovarian cancer survival rates On World Ovarian Cancer Day the Global Ovarian Cancer Research Consortium, of which Ovarian Cancer Research Alliance (OCRA) is … Continued
Accelerating the Mission: OCRA President & CEO Audra Moran Named a Crain’s 2026 Notable Leader in Health Care Ovarian Cancer Research Alliance (OCRA) is proud to share that President and CEO Audra Moran has been named a Crain’s New York Business 2026 Notable Leader in Health Care—an annual recognition honoring executives whose leadership, innovation, and … Continued
Audra Moran, President and CEO of Ovarian Cancer Research Alliance (OCRA), has been recognized as a Crain’s New York Business 2026 Notable Leader in Health Care. Crain’s annual recognition spotlights health care executives whose leadership, innovation, and community commitment set a high bar for the field. Honorees are selected based on demonstrated impact, both within … Continued
This article was updated in April 2026 to reflect NCCN’s release of the 2026 Guidelines for Uterine Cancer Patients. OCRA is a proud sponsor of the 2026 Patient Guidelines for Cervical Cancer and Uterine Cancer, and the 2025 Patient Guidelines for Ovarian. We believe ensuring access to clear, understandable information is critical. NCCN provides wonderful … Continued
On March 25, 2026, the U.S. Food and Drug Administration (FDA) approved Lifyorli (relacorilant), made by Corcept Therapeutics, in combination with Abraxane (nab-paclitaxel) for adults with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer who have received one to three prior lines of treatment, including prior Avastin (bevacizumab). The approval follows last month’s FDA … Continued
Get email updates about research news, action alerts, and ways to join the fight.
A global, Al-powered ecosystem designed to transform gynecologic cancer research—connecting patients, researchers, and clinicians to accelerate breakthroughs.
Our website uses cookies to ensure you get the best experience. By continuing to use this website, you indicate that you have read and agree to our Terms of Use and Privacy Policy.
